Streetbeat News

Products Services

APTO

Aptose Biosciences has secured a $10 million loan from Hanmi Pharmaceutical to support the development of its AML treatment, tuspetinib. The companies are also negotiating a new co-development agreement to further accelerate the drug's clinical development.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 8:31 pm

GME

GameStop shares rose by 8.88% to $23.42, driven by upcoming Q2 earnings, a strategic shift in liquidity management, and a retail strategy targeting retro gaming. Despite the stock's rise, retail investor interest remains lower than during the 2021 meme stock frenzy.

Portfolio Pulse from Vaishali Prayag

August 30, 2024 | 8:27 pm

STKH

Steakholder Foods is focusing on securing additional commercial deals, expanding market reach, and launching new product applications. The company anticipates modest revenue generation starting late 2024 or early 2025, with accelerated growth in 2025 from printers and plant-based premixes.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 8:19 pm

BUD

Anheuser-Busch InBev (NYSE:BUD) is attempting to win back conservative consumers with a new Bud Light ad campaign featuring comedian Shane Gillis, targeting college football fans. This move follows a previous boycott due to a controversial partnership with trans activist Dylan Mulvaney.

Portfolio Pulse from Chris Katje

August 30, 2024 | 8:17 pm

ZBAO

Zhibao Technology Inc. (NASDAQ:ZBAO) has won a tender to provide high-end medical third party administration services to the People's Insurance Company of China Limited (PICC Group). This contract, valued at CNY 28 million over three years, designates Zhibao as one of four exclusive vendors for PICC Group subsidiaries. The deal enhances Zhibao's access to PICC's extensive network, benefiting its Managing General Underwriting business and strengthening its digital insurance brokerage operations.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 8:07 pm

IOBT

IO Biotech's Phase 3 trial of IO102-IO103 in combination with KEYTRUDA for advanced melanoma will continue after an IDMC review found no new safety signals. The primary endpoint of progression-free survival is expected in the first half of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 8:07 pm

NVAX

Novavax's COVID-19 vaccine, NVX-CoV2705, has received Emergency Use Authorization from the FDA for individuals aged 12 and older, leading to a rise in Novavax shares.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 7:55 pm

BLIN

Bridgeline Digital's shares rose after announcing that a major aftermarket automotive truck parts retailer selected its HawkSearch technology for eCommerce product discovery.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 7:53 pm

AAL

DIS

IHG

LUV

RCL

WH

Airfares have decreased for Labor Day, but other travel costs like cruises, car rentals, and hotels have risen. Airlines, cruise companies, and hotels mostly traded higher ahead of the holiday weekend.

Portfolio Pulse from Michael Juliano

August 30, 2024 | 7:51 pm

MNOV

MediciNova shares rose following the announcement of a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering MN-166 for post-COVID conditions.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 7:50 pm